Microbot Medical® Secures its First Office-Based Lab (OBL) Customer for the LIBERTY® Endovascular Robotic System

Every customer that has used its initial LIBERTY inventory has subsequently reordered additional systems, Microbot said.

Rhea-AI Summary

Microbot Medical (Nasdaq: MBOT) secured its first office-based laboratory customer, ELMNT IR, through an order for LIBERTY robotic devices. The California outpatient interventional radiology practice signed an order to purchase up to a 12-month supply, becoming the company’s first West Coast customer. Office-based laboratories provide minimally invasive, image-guided procedures outside traditional hospitals.

ELMNT IR has already performed multiple procedures using LIBERTY. Microbot said every customer that has used its initial LIBERTY inventory has subsequently reordered additional systems. The geographic expansion aligns with the company’s Full Market Release strategy.

3 points · 0 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 0 points

How the balance works

Positive

• Moderate pointELMNT IR’s signed order covers up to a 12-month supply of LIBERTY devices.
• Minor pointFirst office-based laboratory and West Coast customer expands Microbot’s commercial reach.
• Minor pointRepeat orders followed initial inventory use at every LIBERTY customer, Microbot said.

Negative

• None.

Argus 15 min delay 3 alerts

+4.49% vs previous close $0.98 last price 4.1x rel. volume Open Argus

Details

Market move: MBOT +4.49% vs previous close. OBL customer order

$0.93 – $0.98 Day Range

$66.09M Mkt Cap at Last Price

On Oct 27, the day this news came out, the latest delayed price for MBOT is 4.49% above the previous close. Our momentum scanner has recorded 3 alerts for this stock so far that day. The latest delayed price is $0.98. Relative volume is very high at 4.1x the average.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Supply order: Up to a 12-month supply

Supply order

Up to a 12-month supply

ELMNT IR order for LIBERTY devices

Historical Context

2 past events · Latest: Sep 25

2 events

1. Sep 25

   Commercial expansion

   24h Move

   -2.0%

   Reported a first California customer and U.S. commercial expansion plans for LIBERTY.

2. Aug 11

   Quarterly results

   24h Move

   -13.2%

   Reported revenue and customer counts increased more than 100% versus Q1 after LIBERTY's Full Market Release.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

office-based laboratory, endovascular, y-90 radioembolization, prostate artery embolization, +1 more

5 terms

office-based laboratory medical

"first Office-Based Laboratory (OBL) customer in the world"

A medical clinic space set up to perform diagnostic or minimally to moderately invasive procedures outside a hospital operating room, equipped with procedure rooms, monitoring and resuscitation equipment, and trained staff so patients can undergo treatments and leave the same day. Office-based laboratories are typically run by physician practices (for example in cardiology, interventional radiology, pain management or gastroenterology) and operate under outpatient/ambulatory regulations and billing rules rather than full hospital rules; specific licensing, accreditation and safety requirements vary by jurisdiction.

endovascular medical

"peripheral endovascular procedures"

Endovascular describes medical procedures performed inside blood vessels using thin tubes, wires, and implantable devices guided by imaging—like repairing a broken pipe from the inside rather than opening the wall. It matters to investors because these less-invasive techniques can shorten hospital stays, lower complication rates and create demand for specialized devices and imaging equipment, so changes in adoption, regulation or reimbursement can materially affect healthcare company revenues and margins.

y-90 radioembolization medical

"before Y-90 radioembolization, for the treatment of liver tumors"

Y-90 radioembolization is a medical procedure that delivers tiny beads carrying the radioactive atom yttrium-90 directly into blood vessels feeding liver tumors, where they lodge and emit focused radiation that shrinks or destroys cancer cells. For investors, it matters because adoption, clinical results, device makers, and reimbursement shape revenue potential and competitive dynamics in the market for liver cancer treatments—think of it as a targeted missile system for tumors rather than broad-area radiation.

prostate artery embolization medical

"Prostate Artery Embolization (PAE) for the treatment of benign prostatic hyperplasia"

Prostate artery embolization is a minimally invasive medical procedure that reduces blood flow to part of the prostate by injecting tiny particles into its arteries, causing targeted tissue shrinkage and symptom relief for urinary problems. For investors, it matters because it involves specialized devices, imaging equipment, and training that can drive demand for medical suppliers, affect hospital service lines and reimbursement decisions, and influence adoption rates for alternative treatments much like a new tool changing how craftsmen work.

benign prostatic hyperplasia medical

"for the treatment of benign prostatic hyperplasia (BPH)"

Benign prostatic hyperplasia is a noncancerous enlargement of the prostate gland that can squeeze the urethra and cause urinary symptoms like weak stream, urgency, and incomplete emptying; think of it as a garden hose being pinched so water flow slows. It matters to investors because it creates steady demand for medications, medical devices and procedures, regulatory approvals, and insurance coverage decisions—factors that can drive revenue and growth in healthcare companies serving an aging population.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ELMNT IR also became the first account on the West Coast, marking a geographic expansion which aligns with the Company’s Full Market Release strategy. 

The Company believes the OBLs represent a rapidly growing healthcare segment and opportunity as many endovascular procedures are being done outside traditional hospital settings and Ambulatory Surgery Centers.

HINGHAM, Mass., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY Endovascular Robotic System, today announced that ELMNT IR, a multisite outpatient interventional radiology practice in California, has signed an order to purchase up to a 12-month supply of LIBERTY devices. ELMNT IR became the first Office-Based Laboratory (OBL) customer in the world to utilize the LIBERTY Endovascular Robotic System, and the Company’s first customer on the West Coast. An OBL is an outpatient care setting that enables physicians to perform minimally invasive, image-guided procedures outside of the traditional hospital environment.

Jonathan Steinberger, M.D., co-founder of ELMNT IR and a board-certified interventional radiologist specializing in minimally invasive, image-guided treatments for vascular disease, cancer, men's health conditions, and complex venous disorders, has already performed multiple procedures using the LIBERTY System, including Y90 mapping, which is a planning procedure performed before Y-90 radioembolization, for the treatment of liver tumors, Prostate Artery Embolization (PAE) for the treatment of benign prostatic hyperplasia (BPH), and Genicular Artery Embolization (GAE) for symptomatic knee osteoarthritis.

“Having used LIBERTY for multiple procedures, I’ve found that the combination of a compact footprint, efficient workflow, and the elimination of upfront capital costs and expenses associated with traditional equipment makes LIBERTY an optimal system for establishing an Endovascular Robotic Program in an OBL,” said Jonathan Steinberger, M.D., Co-Founder and Interventional Radiologist at ELMNT IR. “We have seen firsthand the value it can bring to physicians and patients. Based on our experience to date, LIBERTY is well positioned to become a standard for the use of robotics in endovascular intervention procedures.”

“This is a significant milestone for us, and we believe it supports the value that LIBERTY brings across multiple sites of care settings, especially in OBLs, as we believe they are an important and growing segment of the market,” commented Harel Gadot, Chairman, CEO, President. “Our relationship with ELMNT IR, which has already resulted in advance orders of the LIBERTY System from ELMNT IR, continues a trend in which every customer that has utilized its initial LIBERTY inventory has subsequently reordered additional systems. We believe this reflects high satisfaction among physicians, as well as the acceptance by hospital administration, as they recognize the value of the system. Furthermore, in addition to expanding access to healthcare networks, this represents an additional revenue opportunity for the LIBERTY System as we expect the number of peripheral vascular interventions performed in OBLs to continue to increase.”

LIBERTY is the only FDA cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, and it is designed for precise vascular navigation while aiming to reduce radiation exposure and physical strain.

About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a commercial stage medical device company focused on transforming endovascular procedures through advanced robotic technology. Microbot’s LIBERTY® Endovascular Robotic System is the first single-use, remotely operated robotic solution designed for precision, efficiency and safety. Backed by a strong intellectual property portfolio and a commitment to innovation, Microbot is driving the future of endovascular care.

Learn more at www.microbotmedical.com and connect on LinkedIn and X.

Safe Harbor

Statements relating to future financial and/or operating results, future adoption of products, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “contemplates,” “continues,” “could,” “forecasts,” “intends,” “may,” “might,” “possible,” “potential,” “predicts,” “projects,” “should,” “would,” “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions, risks inherent in the commercialization of the LIBERTY^® Endovascular Robotic System, and in the development of future versions of or applications for the system, market acceptance of the LIBERTY system, the length and outcome of hospital Value Analysis Committee and purchasing processes and the Company’s ability to convert sales leads into orders, uncertainty in the results of regulatory pathways and regulatory approvals, uncertainty resulting from political, social and geopolitical conditions, disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical^® can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical^® disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Contacts:
IR@microbotmedical.com
Media@microbotmedical.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ELMNT IR order from Microbot Medical?

ELMNT IR signed an order to purchase up to a 12-month supply of LIBERTY devices. The California outpatient interventional radiology practice became Microbot’s first office-based laboratory customer and its first customer on the West Coast.

Which procedures has ELMNT IR performed using Microbot’s LIBERTY system?

ELMNT IR has used LIBERTY for Y90 mapping, prostate artery embolization and genicular artery embolization. These procedures respectively support planning before liver-tumor radioembolization, treatment of benign prostate enlargement and treatment of symptomatic knee osteoarthritis.